Lymphoma Biomarker Analysis
Lymphoma Biomarker Analysis - Related Videos
08:28
An Overview of bGDGT Biomarker Analysis for Paleoclimatology
0 Views •
2023
Source: Laboratory of Jeff Salacup - University of Massachusetts Amherst Throughout this series of videos, natural samples were extracted and purified in search of organic compounds, called biomarkers, that can relate information on climates and environments of the past. One of the samples analyzed was sediment. Sediments accumulate over geologic time in basins, depressions in the Earth into which sediment flows through the action of fluid (water or air), movement, and gravity. Two main types...
10:10
An Overview of Alkenone Biomarker Analysis for Paleothermometry
0 Views •
2023
Source: Laboratory of Jeff Salacup - University of Massachusetts Amherst Throughout this series of videos, natural samples were extracted and purified in search of organic compounds, called biomarkers, that can relate information on climates and environments of the past. One of the samples analyzed was sediment. Sediments accumulate over geologic time in basins, depressions in the Earth into which sediment flows through the action of fluid (water or air), movement, and gravity. Two main types...
14:04
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
0 Views •
Cited by 11 •
2016
Neutrophils are the most abundant type of white blood cells. The isolation of neutrophils from human blood by density gradient separation method and the differentiation of human promyelocytic (HL60) cells along the granulocytic pathway are described here; to test their role on sensitivity of lymphoma cells to anti-lymphoma agents.
04:23
Determining the Role of Neutrophil-Like Cells in Lymphoma Cell Sensitivity to a Test Drug
0 Views •
2025
This video demonstrates an assay investigating the role of neutrophil-like cells in safeguarding lymphoma cells against the cytotoxicity of chemotherapeutic agents. A 3D co-culture, consisting of lymphoma and neutrophil-like cells, is established and exposed to vincristine—a chemotherapy drug. Direct contact with the neutrophil-like cells induces an upregulation of anti-apoptotic proteins in the lymphoma cells, thereby promoting their survival in the presence of vincristine.
17:59
Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
0 Views •
Cited by 11 •
2011
In this video we demonstrate a protocol to establish mouse thymic lymphoma cell lines. By following this protocol, we have successfully established several T-cell lines from Atm-/- and p53-/- mice with thymic lymphoma.
FAQs
Different lymphomas can display distinct combinations of molecular, cellular, or tissue features. Analyzing these patterns helps characterize tumor biology rather than treating all lymphomas as identical. The resulting profiles support more precise classification and can connect particular findings with expected clinical outcomes, allowing researchers and clinicians to interpret disease behavior through measurable characteristics.
These methods examine different levels of tumor information. Immunophenotyping evaluates protein expression on cells, histopathology assesses tissue features, and molecular testing detects genetic alterations or other molecular signals. Their complementary findings provide a broader characterization of a tumor sample, strengthening classification when cellular, tissue, and molecular evidence need to be considered together.
Biomarker findings can be interpreted in relation to different clinical questions. Some patterns help characterize likely disease behavior and clinical outcomes, supporting prognosis, while others inform treatment selection by identifying features relevant to targeted approaches. This dual use links measurable tumor properties with both expectations about disease and decisions about personalized cancer care.
Analysis performed on tumor samples, blood, or lymph node tissue can provide information about disease status at different points in care. Comparing findings over time may help evaluate response to treatment or identify evidence associated with recurrence. This monitoring role extends biomarker analysis beyond initial characterization and connects laboratory results with changing clinical status.
The available analysis may draw on tumor samples, blood, or lymph node tissue, depending on the biological information being examined. Immunophenotyping, histopathology, and molecular testing then assess protein expression, tissue characteristics, genetic alterations, or other signals. Combining an appropriate sample with the relevant method helps generate evidence for classification, prognosis, treatment, or monitoring.
A combined workflow can examine the same disease from complementary perspectives. Histopathology contributes tissue-level information, immunophenotyping identifies cellular protein patterns, and molecular testing evaluates genetic or related signals. Considering these results together can strengthen diagnostic precision because no single level of evidence fully represents the tumor biology captured across molecular, cellular, and tissue measurements.
It is valuable when disease classification, expected outcome, treatment selection, or response monitoring requires more precise biological information. In research, linking biomarker patterns with tumor biology and clinical outcomes supports investigation of targeted therapies. In care, the same evidence contributes to personalized treatment planning and assessment of whether disease responds or returns.
The approach connects measurable features of lymphoma cells and tissues with the underlying biology of the tumor. Researchers can relate protein expression, genetic alterations, and other signals to clinical outcomes, creating a basis for studying targeted therapies. This relationship also supports personalized cancer care by connecting biological variation with treatment selection and disease monitoring.